NDC 70436-015

NDC codes

FDA NDC Directory

Product NDC (as listed)70436-015Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70436-0015Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70436-015-04	70436001504	30 TABLET, FILM COATED in 1 BOTTLE (70436-015-04)Marketed from May 15, 2025
70436-015-06	70436001506	90 TABLET, FILM COATED in 1 BOTTLE (70436-015-06)Marketed from May 15, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide
Generic name (nonproprietary): olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide
Active ingredients: Olmesartan medoxomil — 40 mg/1Amlodipine besylate — 5 mg/1Hydrochlorothiazide — 12.5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Slate Run Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210718
Marketing start: May 15, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Angiotensin 2 Receptor Antagonists (Mechanism)Calcium Channel Antagonists (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Dihydropyridines (Chemical structure)Increased Diuresis (Physiologic effect)Thiazides (Chemical structure)
Identifiers: Product ID 70436-015_d306cb9e-4244-49dd-9297-9cb6ca69cae9SPL ID d306cb9e-4244-49dd-9297-9cb6ca69cae9SPL set ID a469adff-25a6-4983-b471-60924d920a86RxCUI 999967, 999986, 999991, 999996, 1000001UNII 0J48LPH2TH, 864V2Q084H, 6M97XTV3HDUPC 0370436018048, 0370436016044, 0370436014040, 0370436015047, 0370436017041
Pharmacologic class: Angiotensin 2 Receptor Blocker; Calcium Channel Blocker; Dihydropyridine Calcium Channel Blocker; Thiazide Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470436001504 followed by a unit qualifier and the quantity

Package 70436-0015-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 30, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardio…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210718

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210718
Product	Strength	Form · route	Labeler	Product NDC
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	Olmesartan medoxomil 40 mg/1 + 2 more ingredients	Tablet, Film coatedOral	Slate Run Pharmaceuticals, LLC	70436-016
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	Olmesartan medoxomil 20 mg/1 + 2 more ingredients	Tablet, Film coatedOral	Slate Run Pharmaceuticals, LLC	70436-014
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	Olmesartan medoxomil 40 mg/1 + 2 more ingredients	Tablet, Film coatedOral	Slate Run Pharmaceuticals, LLC	70436-017
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	Olmesartan medoxomil 40 mg/1 + 2 more ingredients	Tablet, Film coatedOral	Slate Run Pharmaceuticals, LLC	70436-018

olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide NDC 70436-015